Volume 21, Issue 7, Pages (November 2017)

Slides:

Advertisements

Similar presentations

Genome Engineering with CRISPR-Cas9 in the Mosquito Aedes aegypti

Advertisements

Irreplaceability of Neuronal Ensembles after Memory Allocation Naoki Matsuo Cell Reports Volume 11, Issue 3, Pages (April 2015) DOI: /j.celrep

Quantitative ChIP-Seq Normalization Reveals Global Modulation of the Epigenome David A. Orlando, Mei Wei Chen, Victoria E. Brown, Snehakumari Solanki,

Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M Shigeru.

Nucleotide Pool Depletion Induces G-Quadruplex-Dependent Perturbation of Gene Expression Charikleia Papadopoulou, Guillaume Guilbaud, Davide Schiavone,

MiR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells Mathieu Neault, Frédérick A. Mallette, Stéphane Richard Cell.

Elephantid Genomes Reveal the Molecular Bases of Woolly Mammoth Adaptations to the Arctic Vincent J. Lynch, Oscar C. Bedoya-Reina, Aakrosh Ratan, Michael.

Figure 1 Overview of the IMPACT Analysis Pipeline

Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma Fred C. Lam, Michael B. Yaffe Cancer.

Volume 5, Issue 1, Pages (October 2013)

Oncogenic BRAF-Mediated Melanoma Cell Invasion

Nicholas McGranahan, Charles Swanton Cell

Intratumor and Intertumor Heterogeneity in Melanoma

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

C. Allison Stewart, Lauren Averett Byers Cancer Cell

Radiotherapy Complements Immune Checkpoint Blockade

Revealing the genomic heterogeneity of melanoma

Genetics and Genomics in the Practice of Medicine

Volume 4, Issue 6, Pages (September 2013)

Volume 17, Issue 1, Pages (January 2010)

Volume 27, Issue 3, Pages (March 2015)

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

Toward a Survey of Somatic Mutation of the NF1 Gene in Benign Neurofibromas of Patients with Neurofibromatosis Type 1 Ingrid Eisenbarth, Kim Beyer, Winfrid.

Volume 165, Issue 1, Pages (March 2016)

Learning the ABCs of Melanoma-Initiating Cells

Implementing Genome-Driven Oncology

PHIPing Out: A Genetic Basis for Tumor Ulceration

Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma Rachel D. Melamed, Iraz T. Aydin, Geena Susan Rajan, Robert.

Volume 20, Issue 9, Pages (August 2017)

Clinical Genomics in Inflammatory Bowel Disease

Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma Cynthia Spittle, M. Renee Ward, Katherine.

Volume 4, Issue 3, Pages (August 2013)

Figure 2 Frequency and overlap of alterations

Lung Cancer: A Wily Genetic Opponent

Volume 21, Issue 7, Pages (November 2017)

Volume 24, Issue 4, Pages (July 2018)

Volume 29, Issue 3, Pages (March 2016)

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Guidelines for Large-Scale Sequence-Based Complex Trait Association Studies: Lessons Learned from the NHLBI Exome Sequencing Project Paul L. Auer, Alex.

Volume 22, Issue 1, Pages (January 2018)

Volume 17, Issue 8, Pages (November 2016)

The RAF Inhibitor Paradox Revisited

Circulating Tumor Cells and Melanoma Progression

Volume 24, Issue 8, Pages (August 2018)

Patricia Munoz-Garrido, Jesper B. Andersen Gastroenterology

Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery

C. Allison Stewart, Lauren Averett Byers Cancer Cell

Volume 31, Issue 2, Pages (February 2017)

Principles and Strategies for Developing Network Models in Cancer

Mizuho Fukunaga-Kalabis, Meenhard Herlyn

Unraveling the Mysteries of IGF-1 Signaling in Melanoma

521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies Molecular Therapy Volume 22, Pages.

Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug- Resistant Basal Cell Carcinoma Scott X. Atwood, Kavita Y. Sarin, Jiang.

Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes Brian H. Shirts, Eric Q. Konnick, Sarah Upham, Tom Walsh, John Michael.

Volume 11, Issue 9, Pages (June 2015)

Andrew R. Bassett, Charlotte Tibbit, Chris P. Ponting, Ji-Long Liu

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

Volume 167, Issue 2, Pages e9 (October 2016)

Volume 20, Issue 9, Pages (August 2017)

Volume 9, Pages (November 2018)

Padmanee Sharma, James P. Allison Cell

Volume 163, Issue 4, (November 2015)

Volume 30, Issue 3, Pages (September 2016)

Learning the ABCs of Melanoma-Initiating Cells

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Volume 23, Issue 11, Pages (November 2015)

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Core melanoma escape pathways during disease progression on BRAF inhibitor therapy. Core melanoma escape pathways during disease progression on BRAF inhibitor.

Presentation transcript:

Volume 21, Issue 7, Pages 1936-1952 (November 2017) Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines Bradley Garman, Ioannis N. Anastopoulos, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Yuchao Jiang, Bradley Wubbenhorst, Ravi Amaravadi, Joseph Bennett, Marilda Beqiri, David Elder, Keith T. Flaherty, Dennie T. Frederick, Tara C. Gangadhar, Michael Guarino, David Hoon, Giorgos Karakousis, Qin Liu, Nandita Mitra, Nicholas J. Petrelli, Lynn Schuchter, Batool Shannan, Carol L. Shields, Jennifer Wargo, Brandon Wenz, Melissa A. Wilson, Min Xiao, Wei Xu, Xaiowei Xu, Xiangfan Yin, Nancy R. Zhang, Michael A. Davies, Meenhard Herlyn, Katherine L. Nathanson Cell Reports Volume 21, Issue 7, Pages 1936-1952 (November 2017) DOI: 10.1016/j.celrep.2017.10.052 Copyright © 2017 The Authors Terms and Conditions

Cell Reports 2017 21, 1936-1952DOI: (10.1016/j.celrep.2017.10.052) Copyright © 2017 The Authors Terms and Conditions

Figure 1 Variability among Four Different Sample Types (PDX CL, PDX, Patient Tumor, and Cell Line) (A) Average number of deleterious variants detected per sample. (B) Average number of total filtered variants detected per sample. (C) Allelic fractions across the four sample types. (D) Major subtypes (BRAF hotspot, RAS hotspot, NF1 hotspot, and WT/WT/WT) and their differential distribution among the entire cohort. Cell Reports 2017 21, 1936-1952DOI: (10.1016/j.celrep.2017.10.052) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Mutational and Copy Number Profile of Naive Melanoma Cell Lines, PDXs, PDX CLs, and Tumors A single sample from each of 225 unique patients is included. NMVD, no missense variants in targeted genes detected. Cell Reports 2017 21, 1936-1952DOI: (10.1016/j.celrep.2017.10.052) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Mutational and Copy Number Profile of PDXs, PDX CLs, and Tumors from Patients that Received Targeted Therapy with BRAFi, MEKi, or a Combination (A) A single sample from each of 49 unique patients is included. (B) Five subtypes of potential resistance mechanisms in samples that progressed post-treatment. Cell Reports 2017 21, 1936-1952DOI: (10.1016/j.celrep.2017.10.052) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Mutational and Copy Number Profile of PDXs, PDX CLs, and Tumors from Patients that Received Immunotherapy with Anti-CTLA-4, Anti PD-1, or a Combination A single sample from each of 49 unique patients is included. NMVD, no missense variants in targeted genes detected. Cell Reports 2017 21, 1936-1952DOI: (10.1016/j.celrep.2017.10.052) Copyright © 2017 The Authors Terms and Conditions

Figure 5 Mutational and Copy Number Profile in Unique Patient Cell Lines and PDXs with a Likely Deleterious/Deleterious Mutation in Chromatin-Remodeling Genes, which Reveals Mutual Exclusivity of Mutations Cell Reports 2017 21, 1936-1952DOI: (10.1016/j.celrep.2017.10.052) Copyright © 2017 The Authors Terms and Conditions